|
UA68327C2
(en)
*
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
|
US7118754B1
(en)
*
|
1996-07-30 |
2006-10-10 |
Transgene S.A. |
Pharmaceutical composition for treating papillomavirus tumors and infection
|
|
EP0951555A2
(en)
*
|
1996-09-24 |
1999-10-27 |
Bavarian Nordic Research Institute A/S |
Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
|
|
MY119381A
(en)
*
|
1996-12-24 |
2005-05-31 |
Gsf Forschungszentrum Umwelt |
Recombinant mva virus, and the use thereof
|
|
US6969609B1
(en)
*
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
FR2784997A1
(fr)
*
|
1998-10-22 |
2000-04-28 |
Transgene Sa |
Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
|
|
US20040265324A1
(en)
*
|
1999-03-23 |
2004-12-30 |
Cardosa Mary Jane |
Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
|
|
DE60040662D1
(de)
*
|
1999-05-28 |
2008-12-11 |
Helmholtz Zentrum Muenchen |
Vektor zur integration von heterologen sequenzen in poxvirusgenomen
|
|
US20150231227A1
(en)
*
|
2000-03-02 |
2015-08-20 |
Emory University |
Compositions and methods for generating an immune response
|
|
RU2280075C2
(ru)
|
2000-03-14 |
2006-07-20 |
Бавариан Нордик А/С |
Измененный штамм модифицированного вируса коровьей оспы ankara (mva)
|
|
RU2217162C2
(ru)
*
|
2000-04-10 |
2003-11-27 |
Государственный научный центр вирусологии и биотехнологии "Вектор" |
Вакцина против вирусных инфекций
|
|
DE10042598A1
(de)
*
|
2000-08-30 |
2002-03-28 |
Gsf Forschungszentrum Umwelt |
Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
|
|
WO2002031168A2
(en)
*
|
2000-10-10 |
2002-04-18 |
Genstar Therapeutics |
Minimal adenoviral vector and recombinant vaccines based thereon
|
|
CN101676389A
(zh)
|
2000-11-23 |
2010-03-24 |
巴法里安诺迪克有限公司 |
改良安卡拉痘苗病毒变体
|
|
US7445924B2
(en)
|
2000-11-23 |
2008-11-04 |
Bavarian Nordic A/S |
Modified Vaccinia Ankara virus variant and cultivation method
|
|
US7628980B2
(en)
|
2000-11-23 |
2009-12-08 |
Bavarian Nordic A/S |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
US7740863B2
(en)
|
2001-04-06 |
2010-06-22 |
Merial |
Recombinant vaccine against West Nile Virus
|
|
DE10143490C2
(de)
*
|
2001-09-05 |
2003-12-11 |
Gsf Forschungszentrum Umwelt |
Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
|
|
DE10144664B4
(de)
*
|
2001-09-11 |
2005-06-09 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
|
|
AU2002356690B2
(en)
|
2001-12-04 |
2008-07-24 |
Bavarian Nordic A/S |
Flavivirus NS1 subunit vaccine
|
|
US7056723B2
(en)
*
|
2001-12-20 |
2006-06-06 |
Bavarian Nordic A/S |
Method for the recovery and purification of poxviruses from infected cells
|
|
DK1420822T4
(en)
†
|
2002-04-19 |
2017-10-09 |
Bavarian Nordic As |
Modified vaccinia virus Ankara for vaccination of newborns
|
|
PL218318B1
(pl)
|
2002-05-16 |
2014-11-28 |
Bavarian Nordic As |
Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
|
|
CA2481783A1
(en)
*
|
2002-05-16 |
2003-11-27 |
Bavarian Nordic A/S |
Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
|
|
US7501127B2
(en)
|
2002-05-16 |
2009-03-10 |
Bavarian Nordic A/S |
Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
|
|
AU2003264144C1
(en)
|
2002-09-05 |
2009-12-17 |
Bavarian Nordic A/S |
Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
|
|
DE10249390A1
(de)
*
|
2002-10-23 |
2004-05-13 |
Ruprecht-Karls-Universität Heidelberg |
Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
|
|
AU2003293675B2
(en)
|
2002-11-25 |
2009-04-23 |
Bavarian Nordic A/S |
Recombinant poxvirus comprising at least two cowpox ATI promoters
|
|
DE602004015418D1
(de)
*
|
2003-02-18 |
2008-09-11 |
Helmholtz Zentrum Muenchen |
Rekombinantes mva und verfahren zur erzeugung davon
|
|
EP1601333B1
(en)
*
|
2003-02-20 |
2013-01-23 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services |
Novel insertion sites in pox vectors
|
|
US7731974B2
(en)
*
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
AU2004223808B2
(en)
|
2003-03-27 |
2009-03-26 |
Ottawa Health Research Institute |
Mutant vesicular stomatitis viruses and use thereof
|
|
US7163685B2
(en)
*
|
2003-04-16 |
2007-01-16 |
City Of Hope |
Human cytomegalovirus antigens expressed in MVA and methods of use
|
|
GB2402391A
(en)
*
|
2003-06-04 |
2004-12-08 |
Oxxon Pharmaccines Ltd |
Fowlpox recombinant genome
|
|
DE602004031681D1
(de)
|
2003-07-21 |
2011-04-14 |
Transgene Sa |
Multifunktionelle Cytokine
|
|
US20100189747A1
(en)
*
|
2003-07-31 |
2010-07-29 |
Raymond Weinstein |
Compositions and methods for treating or preventing hiv infection
|
|
EP1518932A1
(en)
|
2003-09-29 |
2005-03-30 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Modified vaccinia virus Ankara (MVA) mutant and use thereof
|
|
DE602004009743T2
(de)
*
|
2003-11-24 |
2008-08-28 |
Bavarian Nordic A/S |
Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
|
|
WO2005054451A1
(ja)
|
2003-12-05 |
2005-06-16 |
Hokkaido Technology Licensing Office Co., Ltd. |
高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
|
|
EP1683870A1
(en)
*
|
2005-01-24 |
2006-07-26 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vaccines based on the use of MVA
|
|
US20090269365A1
(en)
*
|
2005-04-20 |
2009-10-29 |
University Of Washington |
Immunogenic vaccinia peptides and methods of using same
|
|
EP2023954B1
(en)
*
|
2006-05-19 |
2013-07-17 |
Sanofi Pasteur, Inc. |
Immunological composition
|
|
ES2611975T3
(es)
*
|
2006-06-20 |
2017-05-11 |
Transgene S.A. |
Procedimiento para producir poxvirus y composiciones de poxvirus
|
|
US7972605B2
(en)
*
|
2006-09-08 |
2011-07-05 |
Duke University |
Modified vaccinia ankara virus vaccine
|
|
CN102026645B
(zh)
|
2006-09-15 |
2016-01-27 |
渥太华医院研究机构 |
溶瘤弹状病毒
|
|
EP2073837B1
(en)
|
2006-10-06 |
2014-06-25 |
Bavarian Nordic Inc. |
Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer
|
|
US20080241139A1
(en)
*
|
2006-10-31 |
2008-10-02 |
Regents Of The University Of Colorado |
Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
|
|
US8557764B2
(en)
*
|
2007-01-26 |
2013-10-15 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods of modulating immune function
|
|
JP2010526528A
(ja)
|
2007-05-03 |
2010-08-05 |
メディツィニーチェ ウニベルシタット インスブルック |
補体因子ｈ由来ショートコンセンサスリピート−抗体構築物
|
|
US8003364B2
(en)
|
2007-05-14 |
2011-08-23 |
Bavarian Nordic A/S |
Purification of vaccinia viruses using hydrophobic interaction chromatography
|
|
US8012738B2
(en)
*
|
2007-05-14 |
2011-09-06 |
Bavarian Nordic A/S |
Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
|
|
US8003363B2
(en)
|
2007-05-14 |
2011-08-23 |
Bavarian Nordic A/S |
Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
|
|
US20100285050A1
(en)
*
|
2007-10-05 |
2010-11-11 |
Isis Innovation Limited |
Compositions and Methods
|
|
BRPI0800485B8
(pt)
*
|
2008-01-17 |
2021-05-25 |
Univ Minas Gerais |
vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
|
|
EP2240573A4
(en)
|
2008-02-12 |
2011-08-31 |
Sanofi Pasteur Ltd |
METHODS OF USING ION EXCHANGE CHROMATOGRAPHY AND DIFFUSION EXCLUSION CHROMATOGRAPHY FOR PURIFYING POXVIRUS
|
|
US20110052627A1
(en)
*
|
2008-06-20 |
2011-03-03 |
Paul Chaplin |
Recombinant modified vaccinia virus measles vaccine
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
WO2010127115A1
(en)
|
2009-04-30 |
2010-11-04 |
Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) |
Modified immunization vectors
|
|
BR112012002628B1
(pt)
|
2009-08-07 |
2021-09-08 |
Transgene Sa |
Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
|
|
EP2501405A4
(en)
*
|
2009-11-20 |
2013-12-04 |
Inviragen Inc |
COMPOSITION, METHOD, AND USES OF POX VIRUS ELEMENTS IN VACCINATE CONSTRUCTS
|
|
US9005632B2
(en)
|
2009-11-20 |
2015-04-14 |
Takeda Vaccines, Inc. |
Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
|
|
WO2011119920A2
(en)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
|
GB201006405D0
(en)
*
|
2010-04-16 |
2010-06-02 |
Isis Innovation |
Poxvirus expression system
|
|
US20110262965A1
(en)
*
|
2010-04-23 |
2011-10-27 |
Life Technologies Corporation |
Cell culture medium comprising small peptides
|
|
US20140093556A1
(en)
|
2011-01-28 |
2014-04-03 |
Sanofi Pasteur Sa |
Immunological Compositions Against HIV
|
|
WO2012151272A2
(en)
|
2011-05-02 |
2012-11-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
SMT201800284T1
(it)
|
2011-06-10 |
2018-07-17 |
Univ Oregon Health & Science |
Glicoproteine cmv e vettori ricombinanti
|
|
ES2813413T3
(es)
*
|
2011-08-05 |
2021-03-23 |
Sillajen Biotherapeutics Inc |
Métodos y composiciones para la producción de virus vaccina
|
|
EP2568289A3
(en)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
|
WO2013046034A2
(en)
*
|
2011-09-26 |
2013-04-04 |
Theravectys |
Use of non-subtype b gag proteins for lentiviral packaging
|
|
EP2586461A1
(en)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Viral particles derived from an enveloped virus
|
|
DK2788021T3
(en)
|
2011-12-09 |
2017-04-10 |
Bavarian Nordic As |
POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
|
|
EP2620446A1
(en)
|
2012-01-27 |
2013-07-31 |
Laboratorios Del Dr. Esteve, S.A. |
Immunogens for HIV vaccination
|
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
|
WO2014009438A2
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterial antigen vaccine
|
|
WO2014043535A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions for the treatment of cancer
|
|
EP3587455A1
(en)
|
2012-10-23 |
2020-01-01 |
Emory University |
Gm-csf and il-4 conjugates, compositions, and methods related thereto
|
|
US20140286981A1
(en)
|
2013-03-14 |
2014-09-25 |
Wisconsin Alumni Research Foundation |
Broadly reactive mosaic peptide for influenza vaccine
|
|
DE102013004595A1
(de)
|
2013-03-15 |
2014-09-18 |
Emergent Product Development Germany Gmbh |
RSV-Impfstoffe
|
|
EP2848937A1
(en)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Methods of identifying novel HIV-1 immunogens
|
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
US10765731B2
(en)
|
2014-01-09 |
2020-09-08 |
Transgene Sa |
Fusion of heterooligomeric mycobacterial antigens
|
|
GB201412494D0
(en)
*
|
2014-07-14 |
2014-08-27 |
Ospedale San Raffaele And Fond Telethon |
Vector production
|
|
HUE053585T2
(hu)
|
2014-09-26 |
2021-07-28 |
Beth Israel Deaconess Medical Ct Inc |
Eljárások és készítmények humán immundeficiencia vírus fertõzés elleni védõ immunválasz indukálására
|
|
US11701418B2
(en)
|
2015-01-12 |
2023-07-18 |
Geovax, Inc. |
Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
|
|
ES3011733T3
(en)
|
2015-02-13 |
2025-04-08 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
PL3390430T3
(pl)
|
2015-12-15 |
2020-03-31 |
Janssen Vaccines & Prevention B.V. |
Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania
|
|
CA3011014A1
(en)
|
2016-01-08 |
2017-07-13 |
Geovax, Inc. |
Compositions and methods for generating an immune response to a tumor associated antigen
|
|
WO2017136419A1
(en)
|
2016-02-03 |
2017-08-10 |
Geovax Inc. |
Compositions and methods for generating an immune response to a flavivirus
|
|
US10736962B2
(en)
*
|
2016-02-25 |
2020-08-11 |
Memorial Sloan Kettering Cancer Center |
Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
|
|
EP3452081A1
(en)
|
2016-05-04 |
2019-03-13 |
Transgene SA |
Combination therapy with cpg tlr9 ligand
|
|
KR102389489B1
(ko)
|
2016-06-16 |
2022-04-22 |
얀센 백신스 앤드 프리벤션 비.브이. |
Hiv 백신 제형
|
|
US10307477B2
(en)
|
2016-09-02 |
2019-06-04 |
Janssen Vaccines & Prevention B.V. |
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
|
|
SG10202001956UA
(en)
|
2016-09-15 |
2020-04-29 |
Janssen Vaccines & Prevention Bv |
Trimer stabilizing hiv envelope protein mutations
|
|
EP3522920A2
(en)
|
2016-10-10 |
2019-08-14 |
Transgene SA |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
BR112019026126A2
(pt)
|
2017-06-15 |
2020-06-30 |
Janssen Vaccines & Prevention B.V. |
vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
|
|
JP7334124B2
(ja)
|
2017-06-21 |
2023-08-28 |
トランジェーヌ |
個別化ワクチン
|
|
EP3655032A1
(en)
|
2017-07-19 |
2020-05-27 |
Janssen Vaccines & Prevention B.V. |
Trimer stabilizing hiv envelope protein mutations
|
|
US20190022212A1
(en)
|
2017-07-21 |
2019-01-24 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
|
|
US20190083620A1
(en)
|
2017-09-18 |
2019-03-21 |
Janssen Vaccines & Prevention B.V. |
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
|
|
US11311612B2
(en)
|
2017-09-19 |
2022-04-26 |
Geovax, Inc. |
Compositions and methods for generating an immune response to treat or prevent malaria
|
|
JP7551496B2
(ja)
|
2017-10-31 |
2024-09-17 |
カリヴィル イムノセラピューティクス， インコーポレイテッド |
全身送達のためのプラットフォーム腫瘍溶解性ベクター
|
|
JP7320601B2
(ja)
|
2018-09-11 |
2023-08-03 |
上▲海▼市公共▲衛▼生▲臨▼床中心 |
広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
|
|
TW202110476A
(zh)
|
2019-05-22 |
2021-03-16 |
荷蘭商傑森疫苗防護公司 |
於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
|
|
KR20220011685A
(ko)
|
2019-05-22 |
2022-01-28 |
길리애드 사이언시즈, 인코포레이티드 |
Tlr7 조절 화합물과 hiv 백신의 조합
|
|
CN114901297A
(zh)
*
|
2019-10-16 |
2022-08-12 |
卡利威尔免疫治疗公司 |
用于原位产生逆转录病毒的生产者病毒
|
|
EP4058058A1
(en)
|
2019-11-14 |
2022-09-21 |
Aelix Therapeutics S.L. |
Dosage regimens for vaccines
|
|
EP3842065A1
(en)
|
2019-12-23 |
2021-06-30 |
Transgene |
Process for designing a recombinant poxvirus for a therapeutic vaccine
|
|
WO2021260065A1
(en)
|
2020-06-24 |
2021-12-30 |
Consejo Superior De Investigaciones Científicas (Csic) |
Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
|
|
EP3928789A1
(en)
|
2020-06-24 |
2021-12-29 |
Consejo Superior de Investigaciones Científicas (CSIC) |
Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
|
|
PE20231175A1
(es)
|
2020-11-19 |
2023-08-01 |
Kalivir Immunotherapeutics Inc |
Inmunoterapia oncolitica por remodelacion del microambiente tumoral
|
|
IL316712B2
(en)
|
2021-04-30 |
2025-12-01 |
Kalivir Immunotherapeutics Inc |
Oncolytic viruses for modified mhc expression
|
|
EP4108257A1
(en)
|
2021-06-23 |
2022-12-28 |
Consejo Superior De Investigaciones Científicas |
Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
|
|
WO2022269003A1
(en)
|
2021-06-23 |
2022-12-29 |
Consejo Superior De Investigaciones Cientificas |
MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
|
|
WO2023077147A2
(en)
|
2021-11-01 |
2023-05-04 |
Pellis Therapeutics, Inc. |
T-cell vaccines for patients with reduced humoral immunity
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
US20230364227A1
(en)
|
2022-05-12 |
2023-11-16 |
Pellis Therapeutics, Inc. |
Poxvirus adjuvant for t-cell vaccination
|
|
EP4316514A1
(en)
|
2022-08-03 |
2024-02-07 |
Consejo Superior de Investigaciones Científicas (CSIC) |
Mva-based vectors and their use as vaccine against sars-cov-2
|
|
AU2024241503A1
(en)
|
2023-03-17 |
2025-08-14 |
Albert-Ludwigs-Universität Freiburg |
Hbv antigen formulation for treating hepatitis b
|
|
WO2025172435A1
(en)
|
2024-02-13 |
2025-08-21 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Hbv antigen formulation for treating hepatitis b
|
|
WO2026041811A1
(en)
|
2024-08-23 |
2026-02-26 |
Transgene |
Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell
|